An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID‐19), but repurposed antivirals have not been successful to date because of redundancy of the target in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Lauren E., FitzGerald, Richard, Saunders, Geoffrey, Lyon, Rebecca, Fisher, Michael, Martin, Karen, Eberhart, Izabela, Woods, Christie, Ewings, Sean, Hale, Colin, Rajoli, Rajith K. R., Else, Laura, Dilly‐Penchala, Sujan, Amara, Alieu, Lalloo, David G., Jacobs, Michael, Pertinez, Henry, Hatchard, Parys, Waugh, Robert, Lawrence, Megan, Johnson, Lucy, Fines, Keira, Reynolds, Helen, Rowland, Timothy, Crook, Rebecca, Okenyi, Emmanuel, Byrne, Kelly, Mozgunov, Pavel, Jaki, Thomas, Khoo, Saye, Owen, Andrew, Griffiths, Gareth, Fletcher, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653087/
https://www.ncbi.nlm.nih.gov/pubmed/34699618
http://dx.doi.org/10.1002/cpt.2463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653087/
https://www.ncbi.nlm.nih.gov/pubmed/34699618
http://dx.doi.org/10.1002/cpt.2463

Ejemplares similares